Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer.
Shohei Udagawa(Japanese Foundation For Cancer Research), Eiji Shinozaki(Japanese Foundation For Cancer Research), Akira Ooki(Japanese Foundation For Cancer Research), Takashi Akiyoshi(The Japanese Society of Gastroenterological Surgery), Takashi Sakamoto(Japanese Foundation For Cancer Research), Shimpei Matsui(Keio University), Toshiki Mukai(Japanese Foundation For Cancer Research), Senzo Taguchi(Japanese Foundation For Cancer Research), Keitaro Shimozaki(Japanese Foundation For Cancer Research), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Tatsuki Noguchi(The University of Tokyo), Koichiro Yoshino(Japanese Foundation For Cancer Research), Takeru Wakatsuki, Hiroki Osumi(Japanese Foundation For Cancer Research), Kensei Yamaguchi(Japanese Foundation For Cancer Research), Keisho Chìn(The Cancer Institute Hospital), Mikako Tamba(Japanese Foundation For Cancer Research), Mariko Ogura(Japanese Foundation For Cancer Research), Shota Fukuoka(National Cancer Research Institute)
Cited by 1
Related Papers
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2021|411